Investigating how a specific leptin receptor variant affects bacterial pneumonia outcomes
Official title: Q223R Leptin Receptor Polymorphism in Bacterial Pneumonia
Funded at University of Michigan at Ann Arbor · NIH-10993097 · Data updated 2026-11-12
This study is looking at how a specific gene change might affect people with bacterial pneumonia, especially those infected with Klebsiella pneumoniae, to see if it influences their immune response and lung damage, with the hope of finding better treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | December 1, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $195,000 |
| NIH project number | 5R21AI180617-02 |
| Project ID | NIH-10993097 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with bacterial pneumonia, especially those who may carry the Q223R leptin receptor polymorphism.
✕Less likely to help
Patients without bacterial pneumonia or those who do not have the Q223R leptin receptor variant may not benefit from this research.
What this research studies
This research focuses on understanding the role of a specific variant of the leptin receptor (Q223R) in patients suffering from bacterial pneumonia, particularly caused by Klebsiella pneumoniae. The study aims to explore how this genetic polymorphism influences neutrophil recruitment and the subsequent lung damage that can occur during severe infections. By examining the immune response and the mechanisms behind excessive neutrophil activity, the research seeks to identify potential therapeutic targets to improve patient outcomes. Patients with this polymorphism may be monitored to better understand their responses to bacterial infections and treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with bacterial pneumonia, particularly those with the Q223R leptin receptor variant.
How similar studies have gone: Previous research has indicated that genetic variations like the leptin receptor polymorphism can significantly impact immune responses, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Mancuso, Peter — University of Michigan at Ann Arbor
- Study coordinator: Mancuso, Peter
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.